BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Singapore includes Novavax XBB.1.5 COVID-19 vaccine under National Vaccination Programme

May 30, 2024 | News

For use in Singapore as an option for ages 12 years and above



Singapore's Ministry of Health has announced that Novavax/Nuvaxovid XBB.1.5 COVID-19 vaccine will be available under the National Vaccination Programme (NVP).

Eligible individuals can receive the Novavax/Nuvaxovid XBB.1.5 vaccine free of charge at any of the participating general practitioner (GP) clinics offering COVID-19 vaccination.

Following approval by the Health Sciences Authority, the Novavax/Nuvaxovid XBB.1.5 COVID-19 vaccine has been recommended by the Expert Committee on Immunisation for use in Singapore as an option for ages 12 years and above, under prevailing COVID-19 vaccination recommendations.

Persons who are unable to receive the COVID-19 mRNA vaccines are recommended to receive the Novavax/Nuvaxovid XBB.1.5 vaccine (a protein subunit vaccine), except those who were diagnosed with myocarditis/pericarditis after a previous dose of an mRNA vaccine.

The previous formulation of the Novavax/Nuvaxovid COVID-19 vaccine, which was based on the original COVID-19 strain, had been discontinued from the NVP since 1 January 2024 when the remaining local stock of the vaccine expired and was no longer supplied by the manufacturer.